Monoclonal antibodies to the circumsporozoite protein repeats of a Plasmodium vivax-like human malaria parasite and Plasmodium simiovale

Udhayakumar, Venkatachalam; Qari, Shoukat H.; Patterson, Pamela S.; Collins, William E.; Lal, Altaf A.

doi:10.1128/iai.62.5.2098-2100.1994

Cited by 5 publications

(2 citation statements)

References 14 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A third variant from a parasite that causes P. vivax malaria in humans, called Plasmodium vivax- like, expresses CSP with APGANQ(E/G)GAA repeats (hereafter named Pv CSP- P. vivax -like) and was described in endemic regions of Papua New Guinea, Brazil, Indonesia and Madagascar 11 . Since the P. vivax- like parasite is among the Plasmodium species that infects NHP 12 , 13 and the Pv CSP- P. vivax -like sequence is identical to P. simiovale CSP 14 , human infections with P. vivax -like parasites are commonly reported as cases of zoonoses 15 , 16 . However, when analyzing the genotype of parasites causing infections characterized microscopically as P. vivax in humans, a significant proportion of the parasites were the P. vivax -like variant, both in single infections and mixed with other Pv CSP allelic variants 17 – 19 .…”

Section: Introductionmentioning

confidence: 99%

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Gimenez

Salman

Marques

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of Plasmodium causing human malaria, P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the P. vivax circumsporozoite protein (PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of PvCSP (VK210, VK247 and P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic P. berghei parasites expressing PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each PvCSP allelic variant. Immunized mice were challenged with two existing chimeric P. berghei parasite lines expressing PvCSP-VK210 and PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant, PvCSP-P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of P. vivax.

show abstract

Section: Introductionmentioning

confidence: 99%

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Gimenez

Salman

Marques

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Two other Plasmodium species closely related to P. vivax have also been identified-Plasmodium cynomolgi and Plasmodium simiovale. Antibodies against the circumsporozoite protein of P. simiovale were detected in human population studies (Qari et al 1993;Udhayakumar et al 1994;Marrelli et al 1998); however, an independent study could not confirm the presence of P. simiovale in the human population (Gopinath et al 1994) and experimental infection of humans with P. simiovale in an early study was not successful (Dissanaike 1965). A recent analysis of the sequence of merozoite surface protein 9 (MSP-9) from diverse Plasmodium species suggests that P. simiovale and the macaque parasite, Plasmodium fieldi, form a clade, whereas P. vivax and P. cynomolgi form another (Chenet et al 2013), arguing for a more in-depth phylogenetic analysis of this species.…”

Section: Adaptation Of P Knowlesi To Human Rbcsmentioning

confidence: 99%

Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination

Lim¹,

Dankwa²,

Paul³

et al. 2017

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

and account for most of the mortality and morbidity associated with malaria in humans. Research and control efforts have focused on infections caused by and , but have neglected other malaria parasite species that infect humans. Additionally, many related malaria parasite species infect nonhuman primates (NHPs), and have the potential for transmission to humans. For malaria elimination, the varied and specific challenges of all of these species will need to be considered. Recent advances in molecular genetics and genomics have increased our knowledge of the prevalence and existing diversity of the human and NHP species. We are beginning to identify the extent of the reservoirs of each parasite species in humans and NHPs, revealing their origins as well as potential for adaptation in humans. Here, we focus on the red blood cell stage of human infection and the host cell tropism of each human species. Determinants of tropism are unique among malaria parasite species, presenting a complex challenge for malaria elimination.

show abstract

Correlation between positive serology for Plasmodium vivax-like/Plasmodium simiovale malaria parasites in the human and anopheline populations in the State of Acre, Brazil

Marrelli

Branquinho²,

Hoffmann

et al. 1998

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

Antibodies against the Plasmodium vivax-like/P. simiovale malaria parasite circumsporozoite repeat peptide (APGANQEGGAA)3 were determined by enzyme-linked immunosorbent assay (ELISA) in 120 sera randomly collected in 1994 from adults in 3 localities of the malaria endemic area in the State of Acre, Brazil; antibody was detected in 18 (15%). A 'sandwich' ELISA using monoclonal antibody (mab) Pam 172, directed against the same peptide, was carried out on 1207 Anopheles oswaldoi, 12 of which (1.0%) were positive, and 168 A. deaneorum, 2 of which (1.2%) were positive. This is the first report of serological detection of the P. vivax-like parasite in anophelines and the first report linking anopheline to human serology for this parasite in the same geographical area. It is an additional indication that A. oswaldoi is a malaria vector in Acre.

show abstract

Monoclonal antibodies to the circumsporozoite protein repeats of a Plasmodium vivax-like human malaria parasite and Plasmodium simiovale

Cited by 5 publications

References 14 publications

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination

Correlation between positive serology for Plasmodium vivax-like/Plasmodium simiovale malaria parasites in the human and anopheline populations in the State of Acre, Brazil

Contact Info

Product

Resources

About